Clinical Trials Browser

Leukemia, Myeloid, Chronic-Phase

NCT02602314 2022-01-20

SUSTRENIM

Phase 4 Unknown

450 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04578847 2020-10-08

READIT

Phase 2 Unknown

100 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03228303 2017-10-10

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

Phase EARLY_PHASE1 Unknown

100 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01690065 2016-05-11

NICE-BORA

Phase 2 Unknown

46 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT02587169 2015-10-27

GEIS-27

Phase 1/2 Unknown

40 enrolled

Sarcoma

Retroperitoneal liposarcoma, Chondrosarcoma, Leiomyosarcoma, Liposarcoma

NCT02389920 2015-03-17

Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

Phase 4 Unknown

40 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01400074 2014-01-13

RE-NICE

Phase 3 Unknown

100 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01168050 2011-02-08

NILOMEL

Phase 2 Unknown

25 enrolled

Dermatologic

Melanoma

Clinical Trials

Nilotinib for First-line Newly Diagnosed CML-CP Patients

SUSTRENIM

READIT

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

NICE-BORA

GEIS-27

Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

RE-NICE

NILOMEL